Takara Bio Inc. (TYO:4974)

Market Cap	95.13B
Revenue (ttm)	45.04B
Net Income (ttm)	1.04B
Shares Out	120.42M
EPS (ttm)	8.65
PE Ratio	91.38
Forward PE	29.38
Dividend	17.00 (2.12%)
Ex-Dividend Date	Mar 28, 2025

Volume	247,600
Average Volume	207,140
Open	788.00
Previous Close	790.00
Day's Range	774.00 - 788.00
52-Week Range	711.00 - 1,186.00
Beta	0.34
RSI	49.24
Earnings Date	Aug 8, 2025

About Takara Bio

Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; geno...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,838
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4974

Financial Performance

In 2024, Takara Bio's revenue was 45.04 billion, an increase of 3.53% compared to the previous year's 43.51 billion. Earnings were 1.04 billion, a decrease of -29.66%.